Migraine management during pregnancy, breastfeeding and in women planning pregnancy
Migraine is a common neurological disorder that predominantly affects women during their reproductive years, presenting unique challenges in the context of pregnancy, breastfeeding, and pregnancy planning. In the present review, we intend to summarize those challenges and propose possible solutions. Women with migraine, particularly those with aura, face an increased risk of pregnancy-related complications, including preeclampsia, stroke, and preterm birth, highlighting the need for careful monitoring throughout gestation. When migraine persists during pregnancy, management should prioritize non-pharmacological approaches, with a strong emphasis on lifestyle modifications and behavioral therapies. In some settings, non-invasive neuromodulation may also be a reasonable option. However, disabling migraine should not be left untreated and may require pharmacological management. Pharmacological treatments should be chosen primarily based on safety considerations, as many migraine medications are not suitable for use during pregnancy. Given the limited safety data available for several treatments, shared decision-making between patients and healthcare providers is essential. During breastfeeding, medication selection should focus on minimizing infant exposure while ensuring effective migraine control for the mother. In women of childbearing potential, caution is needed when prescribing certain migraine treatments, as unplanned pregnancies can occur. Special considerations should also be given to those requiring preventive treatment while planning pregnancy. Given the complexities of migraine management in this population, an individualized approach is crucial to balancing maternal well-being with fetal and infant safety.
Authors
- Mi Ji Lee (ORCID: https://orcid.org/0000-0003-1364-1969)
- Francesca Puledda (ORCID: https://orcid.org/0000-0002-1933-4049)
- Nadine Pelzer (ORCID: https://orcid.org/0000-0003-1763-5443)
- Teshamae Monteith (ORCID: https://orcid.org/0000-0001-8912-252X)
- Faraidoon Haghdoost (ORCID: https://orcid.org/0000-0003-3912-5874)
- Claire H. Sandoe (ORCID: https://orcid.org/0000-0003-1904-2406)
- Patricia Pozo‐Rosich (ORCID: https://orcid.org/0000-0003-0796-4702)
- Simona Sacco (ORCID: https://orcid.org/0000-0003-0651-1939)
- Cristina Tassorelli (ORCID: https://orcid.org/0000-0003-1513-2113)
- Gisela M. Terwindt (ORCID: https://orcid.org/0000-0003-3140-6882)
- Raffaele Ornello (ORCID: https://orcid.org/0000-0001-9501-4031)
- Luigi Francesco Iannone (ORCID: https://orcid.org/0000-0003-3598-0195)
- Antoinette MaassenVanDenBrink (ORCID: https://orcid.org/0000-0001-7176-126X)
- Laura Gómez‐Dabó (ORCID: https://orcid.org/0009-0004-8119-7489)
Institutions
- University of Modena and Reggio Emilia (IT)
- Hebron University (PS)
- Seoul National University (KR)
- University of Miami (US)
- King's College London (GB)
- University of Toronto (CA)
- University of Pavia (IT)
- University of L'Aquila (IT)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Foundation Center (US)
- Seoul National University Hospital (KR)
- UNSW Sydney (AU)
- Vall d'Hebron Institut de Recerca (ES)
- Urology Foundation (GB)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Vall d'Hebron Hospital Universitari (ES)
- The Hague University of Applied Sciences (NL)
Publication Details
- Journal
- Cephalalgia
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1177/03331024251393945
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94